Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

NCT05215106 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT05215106
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215106 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 6, 2021
Completion date
September 15, 2026
Enrollment
200 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

early small (ct1n0) triple negative breast cancer